Development

Cancer Cell publication provides biological rationale for sac-TMT's Phase III push into first-line EGFR-mutant NSCLC

Translational research published in Cancer Cell this week offers a mechanistic rationale for one of the most strategically significant combination studies...

Edited by Robert McTiernan··3 min read
Cancer Cell publication provides biological rationale for sac-TMT's Phase III push into first-line EGFR-mutant NSCLC

A Cancer Cell publication this week offers new biological support for Kelun-Biotech's effort to move sacituzumab tirumotecan (sac-TMT; SKB264/MK-2870) into the first-line treatment of EGFR-mutant non-small cell lung cancer (NSCLC). The translational study, led by investigators at Sun Yat-sen University Cancer Center, found that EGFR tyrosine kinase inhibitor (TKI) treatment upregulates TROP2 expression in residual drug-tolerant persister (DTP) cells, a population thought to contribute to acquired resistance. In preclinical models, sac-TMT combined with AstraZeneca's Tagrisso (osimertinib) suppressed DTP cell formation and delayed tumor recurrence. No clinical efficacy or safety data were reported.

The publication's importance lies less in its immediate findings than in the clinical program it is intended to support. Kelun-Biotech has already completed enrollment in a Phase III registrational trial (NCT06670196) comparing sac-TMT plus osimertinib with osimertinib monotherapy in first-line EGFR-mutant non-squamous NSCLC, and the study is now in follow-up. The Cancer Cell data provide a mechanistic rationale for that strategy, suggesting that EGFR inhibition may create a therapeutic vulnerability through TROP2 upregulation in drug-tolerant persister cells. Whether that biological hypothesis translates into a clinically meaningful delay in resistance and improvement in patient outcomes will ultimately be determined by the Phase III readout.

The resistance problem sac-TMT is trying to solve

Osimertinib monotherapy is the established global standard of care in first-line EGFR-mutant NSCLC, supported by durable progression-free and overall survival data from the FLAURA trial. But resistance is near-universal, driven by a heterogeneous mix of mechanisms including MET amplification, C797S mutation, and histologic transformation. The DTP cell hypothesis — that a small population of cells survives initial TKI exposure and gradually acquires resistance — offers a rationale for intervening with a TROP2-directed ADC early, before resistance is established, rather than after.

The mechanistic logic is that osimertinib induces TROP2 upregulation in the very cells most likely to survive treatment, making those cells more vulnerable to sac-TMT's payload delivery. Whether this translates into meaningful clinical benefit — and at what cost in tolerability — is precisely what NCT06670196 is designed to determine.

Competitive positioning

The first-line EGFR-mutant NSCLC landscape has grown considerably more competitive. AstraZeneca's Tagrisso combined with platinum-based chemotherapy received FDA approval in February 2024 based on the FLAURA2 trial, offering improved progression-free survival over osimertinib monotherapy at the cost of added cytotoxic toxicity. Johnson & Johnson's Rybrevant (amivantamab-vmjw) combined with lazertinib received FDA approval in August 2024 as a chemotherapy-free alternative, based on the MARIPOSA trial, addressing MET-driven resistance mechanisms.

The AllSci BriefFree, systematic R&D and deal news. Daily.

Sac-TMT plus osimertinib would occupy a distinct mechanistic space from both: it avoids traditional cytotoxic chemotherapy while targeting a resistance mechanism — TROP2 upregulation in DTP cells — that neither the chemo combination nor the bispecific antibody approach directly addresses. Cross-trial comparisons are limited by differences in patient populations, endpoints, and follow-up, but the combination's differentiation claim will ultimately rest on the Phase III data.

Strategic context

The Cancer Cell publication arrives at a moment when sac-TMT has accumulated substantial clinical momentum. Phase III OptiTROP-Lung05 data published in The Lancet in May 2026 demonstrated that sac-TMT plus Merck's Keytruda (pembrolizumab) reduced the risk of progression or death by 65% versus pembrolizumab alone in first-line PD-L1-positive NSCLC — the first Phase III ADC-plus-checkpoint inhibitor combination to meet its primary endpoint in this setting. Separately, Phase III OptiTROP-Lung04 data published in the New England Journal of Medicine established sac-TMT as a new standard of care in post-TKI EGFR-mutant NSCLC. The drug now holds four approved indications in China.

Merck (NYSE: MRK), which licensed exclusive rights to develop and commercialize sac-TMT outside Greater China in May 2022, is running 17 ongoing global Phase III studies of the molecule. The breadth of that program means the NCT06670196 readout will be scrutinized not just for its immediate regulatory implications in China, but as a signal of whether sac-TMT can displace or augment osimertinib in the world's largest addressable EGFR-mutant patient population.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

Spot something wrong? Report an issue with this article